190 related articles for article (PubMed ID: 38128340)
1. Advances and considerations in the use of immunotherapies for primary hepato-biliary malignancies.
Gorji L; Brown ZJ; Pawlik TM
Surg Oncol; 2024 Feb; 52():102031. PubMed ID: 38128340
[TBL] [Abstract][Full Text] [Related]
2. Advances in Targeted Immunotherapy for Hepatobiliary Cancers.
Ruff SM; Shannon AH; Pawlik TM
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430440
[TBL] [Abstract][Full Text] [Related]
3. The State of Immunotherapy in Hepatobiliary Cancers.
Ilyas FZ; Beane JD; Pawlik TM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies.
Argemi J; Ponz-Sarvise M; Sangro B
Adv Cancer Res; 2022; 156():367-413. PubMed ID: 35961706
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in Biliary Tract Cancers: Where Are We?
Kalyan A; Khosla H; Kim RD
Curr Oncol Rep; 2022 Dec; 24(12):1821-1828. PubMed ID: 36192517
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.
Cao H; Huang T; Dai M; Kong X; Liu H; Zheng Z; Sun G; Sun G; Rong D; Jin Z; Tang W; Xia Y
Int J Biol Sci; 2022; 18(14):5369-5390. PubMed ID: 36147461
[TBL] [Abstract][Full Text] [Related]
7. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
8. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners].
Voesch S; Bitzer M; Malek N
Radiologe; 2022 Mar; 62(3):200-204. PubMed ID: 35147708
[TBL] [Abstract][Full Text] [Related]
9. Tumor infiltrating T cell states and checkpoint inhibitor expression in hepatic and pancreatic malignancies.
Wan S; Zhao E; Weissinger D; Krantz BA; Werba G; Freeman D; Khanna LG; Siolas D; Oberstein PE; Chattopadhyay PK; Simeone DM; Welling TH
Front Immunol; 2023; 14():1067352. PubMed ID: 36798126
[TBL] [Abstract][Full Text] [Related]
10. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review).
Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H
Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583
[TBL] [Abstract][Full Text] [Related]
11. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages in liver cancer: From mechanisms to therapy.
Cheng K; Cai N; Zhu J; Yang X; Liang H; Zhang W
Cancer Commun (Lond); 2022 Nov; 42(11):1112-1140. PubMed ID: 36069342
[TBL] [Abstract][Full Text] [Related]
13. The Functional Roles of Immune Cells in Primary Liver Cancer.
Pham L; Kyritsi K; Zhou T; Ceci L; Baiocchi L; Kennedy L; Chakraborty S; Glaser S; Francis H; Alpini G; Sato K
Am J Pathol; 2022 Jun; 192(6):826-836. PubMed ID: 35337836
[TBL] [Abstract][Full Text] [Related]
14. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in cholangiocarcinoma.
Al-Rajabi R; Sun W
Curr Opin Gastroenterol; 2021 Mar; 37(2):105-111. PubMed ID: 33507028
[TBL] [Abstract][Full Text] [Related]
16. The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D; Heij LR; Czigany Z; Dahl E; Lang SA; Ulmer TF; Luedde T; Neumann UP; Bednarsch J
J Exp Clin Cancer Res; 2022 Apr; 41(1):127. PubMed ID: 35392957
[TBL] [Abstract][Full Text] [Related]
17. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells.
Polidoro MA; Mikulak J; Cazzetta V; Lleo A; Mavilio D; Torzilli G; Donadon M
World J Gastroenterol; 2020 Sep; 26(33):4900-4918. PubMed ID: 32952338
[TBL] [Abstract][Full Text] [Related]
18. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine.
Rimassa L; Personeni N; Aghemo A; Lleo A
J Autoimmun; 2019 Jun; 100():17-26. PubMed ID: 30862450
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma and cholangiocarcinoma: an update.
Yazici C; Niemeyer DJ; Iannitti DA; Russo MW
Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):63-82. PubMed ID: 24245910
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100354. PubMed ID: 33756174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
